ClinicalTrials.gg
CompletedNCT00392171Updated Jun 7, 2017Results posted

The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)

A Phase 2 interventional study of Temozolomide in Glioma, Astrocytoma and Oligodendroglioma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-06-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2006, registered Oct 2006).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
19 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 112 studies testing temozolomide in Glioma — 13 open to participants now, 18 under way, 2 of them phase 3. Temozolomide · Glioma.

Enrollment
11th of 104
120 · median 41
Started
2006
with 2 others
Phase 2
51 of 112
4 open now
Registered
27th of 112
by date

Among the 112 studies testing temozolomide in Glioma, this one is the 11th largest by enrollment of the 104 interventional ones that give a count, is one of 3 that started in 2006, is one of 51 in phase 2, and was the 27th registered.

Glioma

1,452 studies on the registry are indexed under Glioma; 349 are open to participants now.

Browse Glioma studies →

Open to participants now

13 of the 112 studies testing temozolomide in Glioma are open now, in 10 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 56 (21%) stop at 75 or younger; 62 take children under 18; 15 take healthy volunteers.

This study: 19 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies testing temozolomide in Glioma, or all of them as a file.
02

Study summary

The purpose of this non-randomized, open-label, multicenter, Phase II, 2-stage design, RESCUE study is to test the hypothesis that continuous 28-day oral dosing (28/28) with dose-intense temozolomide (50 mg/m\^2) for up to 12 months may overcome resistance and be effective in the management of adult patients with malignant glioma who have failed following at least 2 cycles (2 months) of conventional 5-day (5/28) cycles of high-dose temozolomide (150-200 mg/m\^2).

03

Conditions studied

  • Glioma
  • Astrocytoma
  • Oligodendroglioma
  • Glioblastoma
04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, greater than 18 years old.
  • Surgically confirmed diagnosis of malignant glioma, specifically anaplastic glioma (anaplastic astrocytoma [AA], anaplastic oligodendroglioma [AO], anaplastic oligoastrocytoma [AOA]) or glioblastoma multiforme (GBM).
  • Must have completed at least 2 cycles (2 months) of conventional 5/28 temozolomide, with radiological evidence of progression.
  • GBM treated with concurrent chemoradiation with temozolomide according to the EORTC/NCIC (European Organization for Research \& Treatment of Cancer/National Cancer Institute of Canada) protocol.
  • Evidence of progression confirmed radiologically (CT [computed tomography] or MRI [magnetic resonance imaging]).
  • Patients must be enrolled within 2 weeks of last radiological confirmation of progression, except for patients undergoing surgical resection.
  • Patients undergoing surgical resection for recurrent disease must be enrolled within 2 weeks of the post-surgical scan.
  • Patients with no residual disease after surgery are allowed.
  • dose should have been stabilized during the last 2 weeks prior to enrollment.
  • Use of medically approved in fertile males and females.
  • Women of must have a negative urine or serum pregnancy test (urinary excretion or serum level of bHCG [beta human chorionic gonadotropin]) within 24 hours of inclusion in the study.
  • (ECOG) score of 0 or 1.
  • Signed form.

Exclusion criteria

Exclusion Criteria:

  • GBM progression during the first 2 months of adjuvant temozolomide (5/28).
  • AA progression during the first 2 months of standard temozolomide therapy (5/28).
  • Chemotherapy for the malignant glioma other than temozolomide.
  • More than one prior course of chemotherapy with temozolomide.
  • Patient evolving from anaplastic glioma to GBM following primary therapy.
  • Patient older than 70 years or who received no conventional chemoradiation regimen.
  • Patient who received radiotherapy for recurrent disease.
  • Patient with disease.
  • Known (HIV) infection.
  • History of non-compliance to other therapies.
  • Inadequate hematological, renal and hepatic function according to all of the following laboratory values (to be performed within 14 days, inclusive, prior to study inclusion):
  • \<=1.5 ×10\^9/L;
  • \<=100 ×10\^9/L;
  • \<90 g/L;
  • Serum creatinine >=1.5 times upper limit of laboratory normal ();
  • Total serum >=1.5 times ULN;
  • ASAT ( [aspartate aminotransferase]) or ALAT (ALT [alanine aminotransferase) >2.0 times ULN;
  • Alkaline phosphatase of >2.5 times ULN.
  • Known chronic or infection.
  • Any other serious medical condition, according to the medical judgment of the physician prior to inclusion in the study.
  • Any medical condition that could interfere with oral medication intake (e.g., frequent vomiting, partial bowel obstruction).
  • Other during the previous 5 years with the exception of surgically cured carcinoma in-situ of the cervix and basal cell carcinoma or non-melanoma skin cancer.
  • Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule as discussed with the patient before inclusion in the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Temozolomide

    Temozolomide will be administered at a dose of 50 mg/m\^2 for cycles of 28 days for 12 months or until progression.

    Drug: Temozolomide

Interventions

  • Subjects will receive temozolomide 50 mg/m\^2 for cycles of 28 days for 12 months or until progression

    Also known as: SCH 52365

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Surviving at Six Months of Treatment Without Evidence of Disease Progression.

    Progression-free survival as determined by Kaplan-Meier method.

    Time frame: 6 months

07

Results

Posted May 17, 2010

Participant flow

Participant flow — Overall Study
MilestoneTemozolomide
Started120
Completed15
Not completed105
Withdrew: Did not meet inclusion criteria4
Withdrew: Disease progression101

Outcome measures

PrimaryPercentage of Participants Surviving at Six Months of Treatment Without Evidence of Disease Progression.

Progression-free survival as determined by Kaplan-Meier method.

Time frame:
6 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Surviving at Six Months of Treatment Without Evidence of Disease Progression.
Percentage of ParticipantsTemozolomide
Anaplastic Glioma (n=28)35.7
Early Glioblastoma Multiforme (GBM) (n=33)27.3
Extended Glioblastoma Multiforme (GBM) (n=27)7.4
Rechallenge Glioblastoma Multiforme (GBM) (n=28)35.7

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Temozolomide—27/120 (22.5%)111/120 (92.5%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventTemozolomide
CONVULSIONNervous system disorders4/120
CONFUSIONAL STATEPsychiatric disorders3/120
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders2/120
PAINGeneral disorders2/120
APHASIANervous system disorders2/120
HEADACHENervous system disorders2/120
LEUKOPENIABlood and lymphatic system disorders1/120
NEUTROPENIABlood and lymphatic system disorders1/120
THROMBOCYTOPENIABlood and lymphatic system disorders1/120
MYOCARDIAL INFARCTIONCardiac disorders1/120
Most frequent other events
Showing 10 of 30
Most frequent other events
EventTemozolomide
FATIGUEGeneral disorders48/120
NAUSEAGastrointestinal disorders35/120
HEADACHENervous system disorders34/120
VOMITINGGastrointestinal disorders24/120
HEMIPARESISNervous system disorders22/120
MEMORY IMPAIRMENTNervous system disorders17/120
CONVULSIONNervous system disorders16/120
CONSTIPATIONGastrointestinal disorders15/120
COUGHRespiratory, thoracic and mediastinal disorders14/120
GAIT DISTURBANCEGeneral disorders13/120

Baseline characteristics

Age, Continuous
Age, Continuous(years)Temozolomide
Mean52 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)Temozolomide
Female44
Male76
Region of Enrollment
Region of Enrollment(participants)Temozolomide
Canada120
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010 Apr 20;28(12):2051-7. doi: 10.1200/JCO.2009.26.5520. Epub 2010 Mar 22. Erratum In: J Clin Oncol. 2010 Jul 20;28(21):3543. PubMed 20308655 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2006 to primary completion in Sep 2009, 39 months.

Results were first posted in May 2010, 8 months after primary completion.

Of 131 phase 2 interventional studies under Glioma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 88. This study's 39 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2006
First posted
Oct 25, 2006
StartActual
Jun 9, 2006
Primary completionActual
Sep 15, 2009
CompletionActual
Sep 15, 2009
Results first posted
May 17, 2010
Last update
Jun 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00392171
Responsible party
Sponsor
First posted
Oct 25, 2006
Start date
Jun 9, 2006
Primary completion
Sep 15, 2009
Completion
Sep 15, 2009
Results posted
May 17, 2010
Last update
Jun 7, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Temozolomide

Start the discussion